Xylometazoline hydrochloride

What it is

Xylometazoline hydrochloride is a synthetic imidazoline, developed at the end of the 1940s almost at the same time as tetrahydrozoline, with clinical trials beginning around 1951. It is used only on the nasal lining, as a metered spray or as drops, usually at 0.1% for adults and at lower strengths for children. It is one of the topical nasal decongestant active ingredients listed in the US over-the-counter monograph, although very few US-labelled xylometazoline products are currently listed on DailyMed; it is far more widely sold in Europe and Asia. Products contain a preservative, which may be benzalkonium chloride or, in the US-listed Sinosil label, thiomersal.

What the research says

Xylometazoline does open a blocked nose, and this is better supported than for the older imidazolines: a placebo-controlled trial in people with a common cold showed a clear objective increase in nasal airflow. What is weak is everything beyond the symptom. The 2016 Cochrane review of decongestant monotherapy, which included xylometazoline among the drugs studied, rated the evidence low quality and found only a small effect on how blocked people felt. Trials of xylometazoline for things other than simple congestion, such as easing a bronchoscope through the nose or helping recovery after nasal surgery, were negative. Its best-documented harm is what happens with prolonged use: the relief window shortens, congestion rebounds, and people keep using it.

Evidence grade: Limited evidence.

How it works

Drug class: Imidazoline alpha-adrenergic receptor agonist (topical nasal decongestant); a full agonist at alpha-2B adrenergic receptors

Xylometazoline is sprayed or dropped into the nose, where it acts as a vasoconstrictor on the nasal submucosa. Constricting those vessels shrinks the swollen lining, which widens the airway and makes breathing through the nose easier. A 2025 review funded by Procter and Gamble International Operations SA places onset of symptom relief at about 5 to 10 minutes, with relief lasting roughly 6 to 10 hours; the same review prints a figure of up to 12 hours but footnotes it as a trend, with significance noted only to 10 hours after application. Prolonged use changes the receptors the drug works through. (Source 1)

What it is used for

• A placebo-controlled trial in 61 people with a cold showed an objective decongestant effect from a single spray that was still significant 10 hours later. The 2016 Cochrane review of decongestants used alone, whose included drugs comprised xylometazoline among others, rated the pooled multi-dose effect on subjective congestion small and the evidence low quality, said the clinical relevance of that small effect is unknown, and was unable to draw any conclusion about single doses. Evidence: limited. (Source 2)
• In a 36-patient study xylometazoline was a stronger acute decongestant than mometasone furoate nasal steroid, measured 15 minutes after one spray against the steroid's 28-day response, but the authors said rhinitis medicamentosa still rules out any preference for long-term use. Evidence: limited. (Source 3)
• A randomised, double-blind, placebo-controlled trial of 148 flexible bronchoscopies found no benefit on ease of nasal passage, pain, mucosal trauma, haemodynamics or complications. No trial of xylometazoline for nasotracheal intubation was retrieved in the searches run, so nothing here speaks to that procedure. Evidence: not-supported. (Source 4)
• A randomised trial of 120 patients found no advantage over saline aerosol and significantly higher pain scores in the xylometazoline group. Evidence: not-supported. (Source 5)

Interactions

• Monoamine oxidase inhibitors (MAOIs) (label): The MAOI warning in the US over-the-counter nasal decongestant monograph is attached to ORAL decongestants, not to topical xylometazoline, and no trial or case report of an MAOI interaction with xylometazoline was found in the literature searched. The concern for a topical imidazoline is therefore inferred from the drug class rather than demonstrated. (Source 6)
• Benzalkonium chloride, the preservative in many nasal sprays (clinical trial): In a randomised, double-blind study of 20 healthy volunteers, an oxymetazoline nasal spray containing benzalkonium chloride produced significantly more rebound swelling and worse evening nasal stuffiness after 30 days of use three times daily than the same spray without the preservative. That trial used oxymetazoline rather than xylometazoline, so the finding is for the drug class. The 2025 review that summarises it describes the evidence as contradictory, and reports a review of 18 studies in which benzalkonium chloride at up to 0.1% appeared safe in intranasal products. (Source 7)
• Alcohol (theoretical): No clinical study or case report of an alcohol interaction with xylometazoline was found in the literature searched. What is documented is that imidazoline overdose itself can depress the central nervous system and breathing and slow the heart, and the 2025 review notes that xylometazoline intoxication reports are few and mostly follow accidental swallowing or dosing errors. (Source 8)
• High blood pressure and the medicines used for it (case reports): Reviews treat existing hypertension as a reason not to use imidazoline nasal decongestants, because the vasoconstriction is not limited to the nose and can raise blood pressure further; stroke risk is described as tied to existing cardiovascular risk plus chronic use rather than to correct dosing. (Source 9)
• Dietary supplements (theoretical): No documented pharmacokinetic study, trial or case report of a supplement interaction with xylometazoline was found in the searches run. The nearest documented interaction in this drug class is between the inhaled decongestant propylhexedrine and kratom, in a 2011 forensic case report recorded in the propylhexedrine entry of this batch, and that involved deliberate misuse rather than normal nasal use; the review quoted here says nothing about it. This absence is an absence of evidence, not evidence of safety. (Source 10)

Stopping it

• Rebound congestion after a short course usually settles on its own within one to two weeks of stopping. The trouble starts when people find that bothersome and keep spraying, which is how the chronic form develops. (Source 11)
• For established rhinitis medicamentosa the published approach is slow withdrawal rather than stopping abruptly, because sudden cessation can worsen rebound. Weaning is combined with intranasal steroids and saline washes, with oral steroids if needed. The reviews state there are no formal clinical guidelines. (Source 12)
• Having come off the drug does not reset the risk: the review reports that people who had previously had rhinitis medicamentosa and had stopped decongestants for more than 12 months did not return to the risk level of people who never had it. It also describes rebound swelling returning where oxymetazoline was used three times a day for seven days, an observation it credits to a 2025 paper which its own reference list resolves to a qualitative analysis of addiction components rather than to a re-exposure experiment. (Source 13)

What goes wrong

Thirty days of xylometazoline use shortened the relief each dose gave from 9 hours to around 5 hours, which is the mechanism by which people end up using more of it. (Source 14)

• Expert review, not systematic, Low certainty.
• Size: not stated in the review.
• Who: people using imidazoline nasal decongestants for prolonged periods.
• How long: 30 days of continuous use.
• Result: effectiveness of each application fell from 9 h to around 5 h after 30 days; attributed to reduced receptor affinity or downregulation of alpha-adrenergic receptors rather than classic tolerance, with the mechanism not fully established. The review gives this figure no citation at all: the parenthetical naming Schäfer et al., 1995 and Zheng et al., 2025 sits at the end of the following sentence, which is about receptor affinity and expression, not after the figure. Graf and Juto 1995, Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling, is in the review’s own reference list and is the plausible origin of the figure, but the review does not cite it here.
• Funding: industry-funded: funded by Procter and Gamble International Operations SA, with one author reporting consulting fees from Procter & Gamble, Reckitt and Chiesi.

With xylometazoline, for example, the effectiveness of the treatment is reduced from 9 h to around 5 h after 30 days of use.

In European pharmacovigilance data, reversible cerebral vasoconstriction syndrome was reported disproportionately often with xylometazoline compared with other decongestants. (Source 15)

• Survey study, Low certainty.
• Size: 65 individual case safety reports of PRES or RCVS with decongestants.
• Who: EudraVigilance reports from 1 January 2001 to 31 December 2025; most reports concerned women aged 18 to 64.
• How long: not applicable.
• Result: reporting odds ratio for RCVS with xylometazoline 3.39 (95% CI 1.94 to 5.93); phenylephrine 2.00 (1.11 to 3.61); PRES disproportionality for ephedrine 6.44 (1.80 to 23.10) and phenylephrine 3.47 (1.22 to 9.88). A reporting odds ratio is a signal of disproportionate reporting, not a measure of risk, and cannot show cause.
• Funding: not stated.

A disproportionate reporting of RCVS was found for xylometazoline (reporting odds ratio, ROR: 3.39; 95% confidence interval, CI: 1.94-5.93) and phenylephrine (ROR: 2.00; 95% CI: 1.11-3.61)

Prolonged use of imidazoline nasal sprays is linked to rebound congestion and to a cycle of escalating use that reviews call privinism, with most regular users unaware of the risk. (Source 13)

• Expert review, not systematic, Low certainty.
• Size: not applicable, narrative review.
• Who: regular users of over-the-counter nasal vasoconstrictors.
• How long: beyond the recommended maximum of 3 to 10 days depending on the product.
• Result: as few as 20% of regular users may be aware of adverse effects and only about a quarter aware of the potential for addiction and the maximum recommended treatment period; after prior rhinitis medicamentosa, rebound swelling returned quickly even after more than 12 months off the drug.
• Funding: industry-funded: funded by Procter and Gamble International Operations SA.

Limit of this finding: Treat both awareness figures as loose. The review gives neither a denominator and hedges both: it says as few as 20% of regular users may be aware of adverse effects, and that only a quarter are aware of the potential for addiction and of the recommended maximum treatment period. Because the 20% is given as a lower bound ("as few as"), the two numbers do not strictly contradict each other, but they cannot be read as a measured split either. The quotation reproduces the review exactly; read it as showing that most regular users are unaware, not as a measurement.

Of the individuals who regularly use nasal vasoconstrictors, as few as 20% may be aware of adverse effects, while only a quarter of regular users are aware of the potential for addiction and the recommended maximum period of treatment

The US Drug Facts label for a xylometazoline nasal spray lists local discomfort as an expected effect and warns that frequent or prolonged use may make congestion recur or worsen. (Source 16)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: adults and children 12 and over using the US-labelled product.
• How long: label limit of 3 days.
• Result: label states the product may cause temporary burning, stinging, sneezing or increased nasal discharge, and that frequent or prolonged use may cause congestion to recur or worsen; it also tells people with heart disease, high blood pressure, thyroid disease, diabetes or prostatic urinary difficulty to ask a doctor first.
• Funding: manufacturer's label, a position with a date, not a trial.

This product may cause temporary discomfort such as burning, stinging, sneezing or an increase in nasal discharge.

The authors of an in vitro ciliary study state as their rationale that xylometazoline does not resolve the epithelial dysfunction of a cold and may itself harm the nasal lining, causing dryness, stinging, burning, rebound congestion and atrophy. (Source 17)

• Lab study in cells, Very low certainty.
• Size: not applicable, an in vitro nasal epithelial model.
• Who: cultured human nasal epithelium.
• How long: not applicable.
• Result: no human outcome measured; this is the stated rationale for developing a xylometazoline plus hyaluronic acid formulation, and is presented here as the authors' background claim rather than as a result.
• Funding: no funding statement in the abstract. Three of the five authors (Simić, Vukelić, Knežević) give their affiliation as Jadran-galenski Laboratorij d.d., Rijeka, a pharmaceutical company, and the other two as the Institute of Cell Biology, University of Ljubljana; the paper’s Declaration of Competing Interest states that the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work. The study was run to develop a combined xylometazoline and hyaluronic acid nasal spray, and the passage quoted here is the authors’ rationale for that product rather than a result.

Unfortunately, this treatment does not resolve the epithelial dysfunction observed in ARS, and its use might negatively impact the nasal mucosa causing issues such as dryness, stinging, burning, rebound congestion, as well as atrophy.

A 2026 narrative review of sympathomimetic decongestants reports that significant events such as myocardial infarction, stroke, hypertensive crises and vasospasm, although rare, have been documented, particularly with excessive use or in combination with other medicines, and states that most of the evidence is case reports. (Source 18)

• Expert review, not systematic, Very low certainty.
• Size: not stated; case reports, observational studies and pharmacovigilance data.
• Who: users of oral and intranasal sympathomimetic decongestants; the section quoted here names no individual drug, and xylometazoline is named in the Background of the same abstract among the drugs the review covers.
• How long: not applicable.
• Result: serious events described as rare and associated particularly with excessive use or combination with other medicines; the review states most clinical evidence comes from case reports rather than high-level studies.
• Funding: not stated.

Numerous reports suggest potentially serious or fatal outcomes, and most clinical evidence comes from case reports rather than high-level studies.

US packaging law treats imidazoline products as a poisoning hazard to children: child-resistant packaging is required for any product containing 0.08 mg or more of an imidazoline. (Source 19)

• Expert review, not systematic, Low certainty.
• Size: not applicable, narrative review.
• Who: households with young children.
• How long: not applicable.
• Result: the Consumer Product Safety Commission's packaging rule requires child-resistant packaging for any over-the-counter or prescription product containing the equivalent of 0.08 mg or more of an imidazoline in a single package; the review notes this has not been replicated globally and that metered sprays are not in themselves child-resistant.
• Funding: industry-funded: funded by Procter and Gamble International Operations SA.

Limit of this finding: The review prints this threshold as “more than 0.08 mg” and credits it to the Poison Prevention Packaging Act 1970. Both are slightly off, and the quotation keeps the review's words. The rule itself, 16 CFR 1700.14(a)(33), covers products containing 0.08 mg or more, so a product at exactly 0.08 mg is included; and the 1970 Act is the enabling statute, while imidazolines were added to the list by a Consumer Product Safety Commission rule decades later.

the US government under the Poison Prevention Packaging Act 1970 added any product containing more than 0.08 mg of imidazoline to a list of substances that must have child-resistant packaging (Ravindra et al., 2024).

What the evidence supports

In a placebo-controlled trial in people with a common cold, xylometazoline 0.1% produced a large objective increase in nasal conductance that was still significant 10 hours after one spray. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 61 patients with a common cold (29 xylometazoline, 32 saline placebo), per the trial's Methods section.
• Who: patients with a common cold.
• How long: 1 spray three times a day for up to 10 days; effect measured over 12 hours.
• Result: nasal conductance at 1 hour 384.23 versus 226.42 cm(3)/s (p at or below 0.0001); peak subjective effect on a visual analogue scale 20.7 mm versus 31.5 mm (p = 0.0298); conductance still superior at 10 hours (p = 0.0009) and a non-significant trend at 12 hours; 8 adverse events on xylometazoline (all mild to moderate) versus 11 on placebo (1 severe)
• Funding: not stated in the abstract; research support recorded as non-US government.

The decongestant effect of xylometazoline was significantly greater than placebo, as shown by the nasal conductance at 1 hour (384.23 versus 226.42 cm(3)/s; p <or= 0.0001) and peak subjective effect (VAS, 20.7 mm versus 31.5 mm; p = 0.0298).

The 2016 Cochrane review of nasal decongestants used alone, whose included drugs comprised xylometazoline among others, found multiple doses gave only a small benefit on subjective congestion on low-quality evidence. (Source 20)

• Systematic review, Low certainty.
• Size: 15 trials, 1838 participants in the review overall; the multi-dose congestion analysis pooled only 2 trials.
• Who: mostly adults with the common cold; 14 of 15 studies were adults only.
• How long: follow-up in multi-dose studies ranged between 1 and 10 days.
• Result: standardised mean difference 0.49, 95% CI 0.07 to 0.92, p = 0.02, rated low-quality evidence, which the review itself calls only a small clinical effect; the congestion pooling was based on two studies, one oral and one topical, and the abstract does not say which drugs those two used, so nothing shows xylometazoline contributed to the 0.49; adverse events 125 per 1000 on treatment against 126 per 1000 on placebo, odds ratio 0.98, 95% CI 0.68 to 1.40, p = 0.90, also low-quality.
• Funding: research support recorded as non-US government; a Cochrane review.

Subjective measures of congestion were significantly better for the treatment group compared with placebo approximately three hours after the last dose (SMD 0.49, 95% confidence interval (CI) 0.07 to 0.92; P = 0.02; GRADE: low-quality evidence). However, the SMD of 0.49 only indicates a small clinical effect.

In 30 healthy adults, xylometazoline and oxymetazoline produced statistically significant decongestion that did not differ between the two drugs on nasal resistance, airflow or most cross-sectional areas, while saline placebo produced no significant change. (Source 21)

• Cohort study, Low certainty.
• Size: 30 healthy adults, 6,300 measurements.
• Who: healthy adults with no nasal disease.
• How long: measurements at baseline and 1, 15, 30 and 60 minutes after dosing.
• Result: significant changes in nasal resistance, airflow and CSA2 and CSA3 after either drug (many p values reported as 0.000), no significant change after placebo, and no significant difference between oxymetazoline and xylometazoline except for CSA3; all 30 subjects were tested with oxymetazoline, xylometazoline and saline and each solution was examined separately, with no randomisation or blinding described and no effect sizes or confidence intervals reported.
• Funding: not stated.

Limit of this finding: This paper prints eight of its p-values as “p = 0.000” and one as “p = 0.00”. A p-value cannot be exactly zero: those are rounded print-outs of p < 0.001, and the second form is a typing error in the source. The source also reports no effect sizes at all, no mean changes and no confidence intervals, so its result that the two drugs did not differ is an absence of evidence of a difference rather than a demonstration that they are equivalent.

A comparison of oxymetazoline and xylometazoline based on nasal resistance, nasal airflow, and CSAs of the nasal cavity demonstrated no statistically significant difference, except for CSA3.

What the evidence does not support

In a randomised, double-blind, placebo-controlled trial of 148 bronchoscopies, xylometazoline did not make passing the bronchoscope through the nose any easier and changed none of the secondary outcomes. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 148 subjects randomised (73 placebo, 75 xylometazoline)
• Who: consecutive adults undergoing flexible bronchoscopy, all with background topical anaesthesia.
• How long: single pre-procedure dose.
• Result: operator-rated ease of negotiation median 1 (IQR 1-2) in both groups, p = 0.79; facial pain 2 (2-4) in both groups, p = 0.36; pain VAS 2 (1-2) placebo versus 2 (1-3) xylometazoline, p = 0.28; trauma VAS 1 (0-2) versus 1 (0-1), p = 0.28; no difference in haemodynamics or complications.
• Funding: not stated; registered as NCT03424889.

Operator rated ease of nasal bronchoscope negotiation (Negotiation VAS) was similar in both the groups [Median (IQR), 1 (1-2) in both groups, p = 0.79].

A randomised trial of nasal surgery aftercare found no benefit of xylometazoline 0.1% spray over saline aerosol, and more pain in the xylometazoline group. (Source 22)

• Randomized trial, Moderate certainty.
• Size: 120 patients.
• Who: patients undergoing septoplasty or functional endoscopic sinus surgery as an isolated procedure.
• How long: symptom scores at day 10 after surgery.
• Result: median pain scores significantly higher with xylometazoline overall (p = 0.03) and in septoplasty patients specifically (p = 0.019); the authors concluded there is no evidence to support xylometazoline over saline.
• Funding: not stated; single-blinded, single centre.

There is no evidence to support the use of xylometazoline hydrochloride 0.1 per cent nasal spray over aerosolised physiological saline alone, following nasal surgery.

Where the evidence is mixed

In persistent allergic rhinitis, xylometazoline was a stronger acute decongestant than a nasal steroid, but its acute response was poorly repeatable and did not predict the steroid response, and the authors said rebound rhinitis still rules out long-term use. (Source 3)

• Randomized trial, Low certainty.
• Size: 36 enrolled, 31 completed per protocol.
• Who: people with persistent allergic rhinitis.
• How long: 15-minute response to xylometazoline compared with 28-day response to mometasone furoate.
• Result: median percentage improvement in peak nasal inspiratory flow 20.0 (95% CI 11.4 to 31.0) for xylometazoline versus 9.6 (3.2 to 15.8) for mometasone; xylometazoline greater for all three outcomes at p<0.05; within-subject standard deviation for percentage improvement to xylometazoline 26.0 for PNIF and 25.2 for nFIV1; no significant correlation between the two drugs' effects.
• Funding: not stated.

Limit of this finding: Randomisation in this study applied only to the mometasone-against-placebo part. The xylometazoline arm was an open challenge measured 15 minutes after a single spray, and it is being compared with a 28-day course of a nasal steroid. “Stronger decongestant” therefore means stronger within 15 minutes, and says nothing about either drug over weeks.

XYLO was a stronger decongestant than MF but rhinitis medicamentosa still precludes any preference for long term XYLO therapy at this time.

An open-label real-world study funded by the product's maker reported improvements in quality-of-life scores during xylometazoline use, but it had no control group. (Source 23)

• Cohort study, Very low certainty.
• Size: 136 enrolled, 102 in the modified intention-to-treat population.
• Who: adults aged 18 and over with early common cold symptoms and a blocked nose.
• How long: up to 7 days of use.
• Result: improvements from day 1 in the plugged nose symptom (p = 0.0023) and in WURSS-21 total and individual quality-of-life scores (p < 0.0001); after the last dose needed, improvements in sleep quality 73%, vitality 76%, physical activity 71%, social activity 80% and sensation 81%; no serious or unexpected adverse events.
• Funding: industry: the product studied was Otrivin, GSK Consumer Healthcare SARL, and the design was decentralised, longitudinal and open-label with no comparator, so improvement cannot be separated from natural recovery from a cold.

Limit of this finding: This study had one arm and no placebo: everyone received xylometazoline. The percentages improving therefore cannot be separated from a cold getting better by itself, and they should not be read beside the controlled effect sizes elsewhere on this page. The paper describes itself as a decentralized, longitudinal, open-label study, and the sponsor, Haleon, makes the product tested.

From day 1, improvements were seen in the 'plugged nose' symptom (p = 0.0023), WURSS-21 total QoL score, and all individual QoL scores (p < 0.0001 for all).

Where the research disagrees

Whether rhinitis medicamentosa is a demonstrated consequence of imidazoline sprays or a condition without clear diagnostic criteria or proof

• Authors of the Procter and Gamble-funded 2025 Frontiers in Pharmacology review, summarising the evidence base, narrative review of in vitro, animal and human studies: The literature around RM is somewhat contradictory due to the subjective nature of the disorder experienced by patients and the evidence available. (Source 24)
• The same review series, describing the documented tolerance mechanism, narrative review; the 9 h to 5 h figure carries no citation in the review - the only parenthetical nearby belongs to the following sentence about receptor affinity - so nothing is offered in support of it: With xylometazoline, for example, the effectiveness of the treatment is reduced from 9 h to around 5 h after 30 days of use. (Source 14)

Whether the benzalkonium chloride preservative contributes to rebound congestion

• Graf, Hallen and Juto (1995), a randomised double-blind study in 20 healthy volunteers - the study the 2025 Procter and Gamble-funded review refers to as “Schäfer et al., 1995”, a citation its own reference list resolves to an unrelated hypertension pharmacology review, randomised double-blind parallel study, 20 healthy volunteers, oxymetazoline three times daily for 30 days: In conclusion, the long-term use of benzalkonium chloride in oxymetazoline nasal spray accentuates the severity of rhinitis medicamentosa in healthy volunteers. (Source 7)
• A review of 18 studies summarised in the same 2025 review (Marple and colleagues, 2004), review of 18 studies: Furthermore, a review of 18 studies indicated that BKC used at a maximum concentration of 0.1% in intranasal products appeared to be safe with minimal evidence of statistically significant differences between BKC treated and control groups (Marple et al., 2004). (Source 25)

How much

• Reference intake: There is no reference intake for a drug. The US Drug Facts label for a 0.1% xylometazoline spray (DailyMed SPL version published 11 February 2011) states: “Adults and children 12 years of age and over: 2 or 3 sprays in each nostril not more often than every 8 to 10 hours. Do not give to children under 12 years of age unless directed by a doctor.” That is the manufacturer's and regulator's position, recorded as a position. (Source 16)
• Upper limit: There is no upper intake level. The US over-the-counter monograph instead caps duration: for xylometazoline hydrochloride nasal sprays, drops or jellies labelled for adults, the label must say “Do not use this product for more than 3 days. Use only as directed. Frequent or prolonged use may cause nasal congestion to recur or worsen. If symptoms persist, consult a doctor.” (21 CFR 341.80(c)(2)(iii), revised as of 1 April 2024). (Source 26)
• Studied: The placebo-controlled common cold trial gave xylometazoline 0.1%, one spray three times a day for up to 10 days. (Source 27)
• Studied: The allergic rhinitis study gave 0.1% xylometazoline as one spray in each nostril, measured 15 minutes later. (Source 3)
• Studied: The real-world quality-of-life study gave xylometazoline hydrochloride 0.1% (Otrivin, GSK Consumer Healthcare SARL, Switzerland) for up to 7 days to adults with early cold symptoms. (Source 28)

A common belief, and what the research shows

The belief: If a decongestant spray stops working as well, you need to use it more often.

What the research shows: That is exactly the cycle the literature describes. A 2025 review reports that “Development of a tolerance towards an imidazoline based nasal treatment results in a shortening window of relief with each dose. With xylometazoline, for example, the effectiveness of the treatment is reduced from 9 h to around 5 h after 30 days of use.” Users then “increase the frequency and/or volume of dose, creating a cycle whereby their symptoms continue to deteriorate although they are being treated”. The US monograph caps labelled use at three days for this reason.

Questions and answers

What is it?

Xylometazoline hydrochloride is a manufactured imidazoline drug, developed at the end of the 1940s with clinical trials from about 1951. It is used only in the nose, as a metered spray or drops. The US monograph's directions for the adult product are written for a 0.1-percent aqueous solution (21 CFR 341.80(d)(2)(vii)(A)(1)); the 2025 review quoted here prints only the 0.05%, 0.025% and 0.01% strengths. It is a relative of naphazoline, tetrahydrozoline and oxymetazoline. (Source 1)

What does it do in the body?

It narrows the blood vessels in the lining under the nasal surface. That shrinks the swollen lining and opens the airway, which is why a blocked nose clears. The review quoted here puts onset within 5 to 10 minutes and relief at between 6 and 10 hours. It also prints a figure of up to 12 hours, which the article footnotes as a trend only, with significance noted until 10 hours after application. (Source 1)

Is it good or bad for you?

Good for a few days, bad beyond that. Over a short course a placebo-controlled trial in 61 people with a cold showed a real objective improvement in airflow. The Cochrane review did not find an increase in adverse events against placebo in the short term, but that is an underpowered null on low-quality evidence, with an interval running from 0.68 to 1.40, which is not the same as showing there is no risk. Used for weeks, the 2025 review reports that the same drug shortens its own window of relief and that users escalate, and the US monograph caps labelled use at three days. (Source 29)

How do you get more of it?

Not a question that applies in the usual sense. Xylometazoline is a manufactured drug, not something the body makes or takes from food, so the only source is a product containing it. In the United States it is one of the topical nasal decongestant active ingredients permitted by the over-the-counter monograph, although very few US-labelled xylometazoline products are currently listed on DailyMed; it is widely sold in Europe and Asia. (Source 30)

We searched: DailyMed drug_name search for xylometazoline, which returned only two US-listed single-ingredient products, and 21 CFR 341.20(b) for the permitted active ingredients

If it is harmful, what reduces it?

When the problem is rebound congestion or rhinitis medicamentosa from prolonged use, the treatment is to come off the spray, weaned slowly rather than stopped suddenly, with intranasal steroids and saline washes alongside and oral steroids if needed. Surgery, nebulised hyaluronic acid or endonasal phototherapy are described for cases where that fails. Reviews stress there are no formal guidelines and no standardised protocol. (Source 12)

Why might someone be low in it or missing it?

Does not apply. Xylometazoline is a manufactured drug ingredient that only enters the body when a nasal product containing it is used, so there is no deficiency and no body store to run low. The US monograph lists it among nasal decongestant active ingredients for use within set dosage limits and dosage forms. (Source 30)

Which whole foods contain it or feed it?

None. Xylometazoline is a synthetic imidazoline derivative and is not present in any food, nor is there anything in the diet that increases or feeds it. The imidazoline nasal decongestants are all laboratory compounds developed from the 1940s onwards. (Source 1)

What happens if you do not have it?

Nothing happens from not having xylometazoline; there is no deficiency state. Without it a blocked nose from a cold stays blocked until the cold resolves. The Cochrane review was unable to say how much that matters: it rated the effect of multi-dose decongestants on congestion small, on low-quality evidence, and said the clinical relevance of that small effect is unknown. (Source 29)

How can you test for it?

There is no clinical test for xylometazoline itself in routine use, and no laboratory test for the condition it causes. The 2025 review states directly that there is no specific biochemical test for rhinitis medicamentosa and that the diagnosis rests on examination and the person's history of nasal vasoconstrictor use; it also notes that clinical findings are non-specific because the symptoms overlap with other causes of congestion. (Source 24)

References

1. Frontiers in Pharmacology. Part 1 - imidazolines and the changing face of nasal decongestants - section 'Xylometazoline'. 2025. PMID 41394151, DOI 10.3389/fphar.2025.1655252. Read the source
2. American Journal of Rhinology. The nasal decongestant effect of xylometazoline in the common cold - Results. 2008. PMID 18655753, DOI 10.2500/ajr.2008.22.3202. Read the source
3. Rhinology. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis - abstract. 2005. PMID 16405274. Read the source
4. Respiratory Investigation. Topical nasal xylometazoline for flexible bronchoscopy (VAIN): a randomized, double-blind, placebo-controlled trial - Results. 2021. PMID 33518471, DOI 10.1016/j.resinv.2020.12.004. Read the source
5. The Journal of Laryngology and Otology. Xylometazoline hydrochloride 0.1 per cent versus physiological saline in nasal surgical aftercare - Results. 2009. PMID 18405405, DOI 10.1017/s002221510800217x. Read the source
6. Code of Federal Regulations, title 21, volume 5, revised as of 1 April 2024 (US Government Publishing Office). 21 CFR 341.80(c)(1)(i) - Labeling of nasal decongestant drug products: warnings, including the monoamine oxidase inhibitor drug interaction precaution, for ORAL nasal decongestants. 2024. Read the source
7. Clinical and Experimental Allergy (British Society for Allergy and Clinical Immunology). Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers - abstract, whole. 1995. PMID 7553241, DOI 10.1111/j.1365-2222.1995.tb01069.x. Read the source
8. Frontiers in Pharmacology. Part 1 - imidazolines and the changing face of nasal decongestants - 'General toxicology', paragraph on xylometazoline and oxymetazoline toxicity. 2025. PMID 41394151, DOI 10.3389/fphar.2025.1655252. Read the source
9. Frontiers in Pharmacology. Part 1 - imidazolines and the changing face of nasal decongestants - section 'Contraindicators for imidazoline nasal decongestant use'. 2025. PMID 41394151, DOI 10.3389/fphar.2025.1655252. Read the source
10. Frontiers in Pharmacology. Part 1 - imidazolines and the changing face of nasal decongestants - 'Safety considerations', opening paragraph. 2025. PMID 41394151, DOI 10.3389/fphar.2025.1655252. Read the source
11. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'Rebound vs. rhinitis medicamentosa', paragraph on time course and withdrawal. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
12. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'Treatment and prevention of rhinitis medicamentosa', paragraph on weaning and adjuncts. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
13. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'Development of tolerance and addiction to imidazoline based nasal treatments', paragraph on awareness and relapse. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
14. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'Development of tolerance and addiction to imidazoline based nasal treatments', opening paragraph. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
15. Pharmacological Reports. The onset of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with the use of decongestant agents: a European pharmacovigilance analysis - Results. 2026. PMID 42432411, DOI 10.1007/s43440-026-00877-z. Read the source
16. Herbion Pakistan Pvt Ltd / DailyMed (US National Library of Medicine), SPL version 1 published 11 February 2011. Sinosil Nasal Decongestant (xylometazoline HCl 0.1%) - US Drug Facts label, complete text of the active ingredient, purpose, use, warnings and directions panel. 2011. Read the source
17. European Journal of Pharmaceutics and Biopharmaceutics. Novel nasal formulation of xylometazoline with hyaluronic acid: In vitro ciliary beat frequency study - abstract, whole. 2023. PMID 37804998, DOI 10.1016/j.ejpb.2023.10.002. Read the source
18. Cardiovascular & Hematological Agents in Medicinal Chemistry. Cardiovascular and Cerebrovascular Events Linked to Abuse and Misuse of Sympathomimetic Nasal Decongestants: A Narrative Review of Clinical Evidence - Results and discussion. 2026. PMID 41603177, DOI 10.2174/0118715257418908251126101911. Read the source
19. Frontiers in Pharmacology. Part 1 - imidazolines and the changing face of nasal decongestants - 'Safety measures to reduce acute risk', paragraph on child-resistant packaging. 2025. PMID 41394151, DOI 10.3389/fphar.2025.1655252. Read the source
20. Cochrane Database of Systematic Reviews (Wiley). Nasal decongestants in monotherapy for the common cold (Cochrane Review) - Main results, multi-dose decongestant versus placebo. 2016. PMID 27748955, DOI 10.1002/14651858.cd009612.pub2. Read the source
21. European Journal of Clinical Pharmacology. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects - Results. 2011. PMID 21069518, DOI 10.1007/s00228-010-0941-z. Read the source
22. The Journal of Laryngology and Otology. Xylometazoline hydrochloride 0.1 per cent versus physiological saline in nasal surgical aftercare - Conclusion. 2009. PMID 18405405, DOI 10.1017/s002221510800217x. Read the source
23. Therapeutic Advances in Respiratory Disease. A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold - Results. 2024. PMID 38372128, DOI 10.1177/17534666241228927. Read the source
24. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'Rebound vs. rhinitis medicamentosa', paragraph on contradictory evidence and absence of a diagnostic test. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
25. Frontiers in Pharmacology. Part II - imidazolines and rhinitis medicamentosa - 'The role of preservatives in rhinitis medicamentosa', paragraph on contradictory benzalkonium chloride evidence. 2025. PMID 41394157, DOI 10.3389/fphar.2025.1655254. Read the source
26. Code of Federal Regulations, title 21, volume 5, revised as of 1 April 2024 (US Government Publishing Office). 21 CFR 341.80(c)(2) - Labeling of nasal decongestant drug products: warnings for topical nasal decongestants, subparagraphs (i) to (x) complete. 2024. Read the source
27. American Journal of Rhinology. The nasal decongestant effect of xylometazoline in the common cold - Methods. 2008. PMID 18655753, DOI 10.2500/ajr.2008.22.3202. Read the source
28. Therapeutic Advances in Respiratory Disease. A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold - Objective and Design sections of the structured abstract, the two adjacent sections each held whole. 2024. PMID 38372128, DOI 10.1177/17534666241228927. Read the source
29. Cochrane Database of Systematic Reviews (Wiley). Nasal decongestants in monotherapy for the common cold (Cochrane Review) - Authors' conclusions. 2016. PMID 27748955, DOI 10.1002/14651858.cd009612.pub2. Read the source
30. Code of Federal Regulations, title 21, volume 5, revised as of 1 April 2024 (US Government Publishing Office). 21 CFR 341.20 - Nasal decongestant active ingredients. 2024. Read the source